Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00073021
Status:
COMPLETED
Last Update Posted:
2015-06-29
First Post:
2003-11-13
Brief Title:
Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis
Sponsor:
Warner Chilcott
Organization:
Warner Chilcott
Study Overview
Official Title:
A Double-Blind Randomized 6-Week Parallel-Group Design Clinical Trial to Assess Safety and Efficacy of Asacol 48 gDay 800 mg Tablet Versus Asacol 24 gDay 400 mg Tablet for the Treatment of Moderately Active Ulcerative Colitis
Status:
COMPLETED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a prospective clinical study to evaluate the safety and efficacy of two different doses of Asacol for the treatment of moderately active ulcerative colitis In addition a new tablet formulation will be evaluated at one of the two doses
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None